

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Status: Recruiting

Eligibility Criteria

This study is NOT accepting healthy volunteers

Conditions & Interventions

Conditions:

Estrogen Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer

Keywords:

HER2+, HR+, breast cancer, malignant tumor of the breast, metastatic breast cancer

More Information

Contact(s): Lauren Aase - lauren.aase@parknicollet.com

Phase: Phase III

IRB Number: 201707881

System ID: NCT02947685

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.